4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 2027 4FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns ...
There’s a new book, “Jumpstart 4D” by Steve Hussey designed to help those new to 4D developing or database publishing in general. It’s published by 4D Press, a division of 4D Inc., developers of the ...
4D Molecular Therapeutics' Phase 2 Expansion Cohort dose selection is expected in Q2 2024 based on all clinical and lung biopsy data. Initial suspension manufacturing process completed in-house at 500 ...
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of ...
4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data In broad population ...
4D Molecular Therapeutics Inc. (NASDAQ:FDMT) is one of the hot stocks to buy with huge upside potential. On October 13, 4D Molecular Therapeutics announced that the company secured up to $11 million ...
The Drexel Drug Discovery and Development (4D) Fellowship Program is a joint effort between Johnson & Johnson Innovative Medicine and Drexel’s Pharmacology and Physiology Department to support ...
RF and microwave specialist Mini-Circuits collaborated with Vayyar, a pioneer in 4D radar imaging, to offer RF/microwave engineers, researchers, and academia a ready-to-use 4D millimeter wave (mmWave) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback